SCHEMBL206293

SCHEMBL206293

CN(C)C1(Cc2cccc(Cl)c2)CCC(NC(=O)CCC(=O)NCCSCc2c(Cl)cccc2Cl)CC1

nearest known ligand 0.51

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
HPGD P15428 6/20 0.51
THRB P10828 1/20 0.51
ALDH1A1 P00352 4/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MAPT P10636 3/20 0.42
TP53 P04637 1/20 0.42
GAA P10253 3/20 0.41
ALOX12 P18054 1/20 0.41
EPHX2 P34913 1/20 0.40
POLB P06746 2/20 0.39
TSHR P16473 1/20 0.39
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL207808 0.92 HPGD (0.55) HPGDTHRBALDH1A1SMN1; SMN2MAPT
SCHEMBL207975 0.89 HPGD (0.43) HPGDTHRBALDH1A1MAPTALOX12
SCHEMBL205735 0.85 ALDH1A1 (0.55) HPGDTHRBALDH1A1SMN1; SMN2MAPT
SCHEMBL204971 0.84 EPHX2 (0.42) HPGDTHRBALDH1A1TP53EPHX2
SCHEMBL208794 0.84 ALDH1A1 (0.44) HPGDTHRBALDH1A1SMN1; SMN2TP53
SCHEMBL208454 0.83 ALDH1A1 (0.53) HPGDTHRBALDH1A1SMN1; SMN2MAPT
SCHEMBL206988 0.83 ALDH1A1 (0.51) HPGDTHRBALDH1A1SMN1; SMN2MAPT
SCHEMBL208016 0.82 HPGD (0.48) HPGDTHRBALDH1A1SMN1; SMN2MAPT
SCHEMBL207438 0.82 ALDH1A1 (0.56) HPGDTHRBALDH1A1SMN1; SMN2MAPT
Hydrochloric Acid SCHEMBL206061 0.82 ALDH1A1 (0.50) HPGDTHRBALDH1A1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US claimed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP claimed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US claimed
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US disclosed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP disclosed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US disclosed
EP-1745010-A1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES Grünenthal GmbH (DE) 2007-01-24 EP disclosed
WO-2005110974-A1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES Grünenthal GmbH (DE) 2005-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds PKD1, DDC, DPYD HPGD 96/4885THRB 4068/4885ALDH1A1 158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.